Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13499
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKershaw, M Hen
dc.contributor.authorDarcy, P Ken
dc.contributor.authorTrapani, Joseph Aen
dc.contributor.authorSmyth, Mark Jen
dc.date.accessioned2015-05-16T03:22:04Z
dc.date.available2015-05-16T03:22:04Z
dc.date.issued1996-12-01en
dc.identifier.citationJournal of Leukocyte Biology; 60(6): 721-8en
dc.identifier.govdoc8975874en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13499en
dc.description.abstractChimeric receptors that redirect effector cell function to tumor cells or virus-infected cells have received much attention. Given the high affinity of Fc(epsilon)RI for immunoglobulin E (IgE) and low serum IgE levels, redirection of effector cells using Fc(epsilon) receptor may provide a novel, versatile, and effective anti-tumor strategy. We have used a mouse perforin 5'-promoter to express a single-chain human Fc(epsilon) receptor in the mouse cytotoxic T lymphocyte cell line, CTLL-R8. Upon ligation of the chimeric Fc(epsilon) receptors by IgE, a signal for effector function is transmitted via the intracellular domain of CD3zeta. Selection in G418-containing medium produced CTLLR8 transfectant clones that: (1) expressed chimeric Fc(epsilon) receptor as determined by flow cytometry; (2) bound human IgE antibodies with high affinity as determined by Scatchard analysis; (3) specifically rosetted IgE-coated SRBC; (4) lysed target cells in IgE-mediated ADCC and reverse ADCC assays; and (5) retarded tumor growth in a Winn assay. Therefore these chimeric Fc(epsilon) receptors can effectively redirect cytotoxicity to tumor cells. Future efforts will assess the versatility and efficacy of these IgE-binding chimeric receptors to redirect killer cell function in animal tumor models.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibody-Dependent Cell Cytotoxicityen
dc.subject.otherAntigens, CD3.chemistryen
dc.subject.otherCytotoxicity, Immunologicen
dc.subject.otherDose-Response Relationship, Immunologicen
dc.subject.otherHumansen
dc.subject.otherImmunoglobulin E.immunologyen
dc.subject.otherImmunotherapyen
dc.subject.otherMembrane Glycoproteins.geneticsen
dc.subject.otherMiceen
dc.subject.otherMice, Inbred C57BLen
dc.subject.otherNeoplasms, Experimental.therapyen
dc.subject.otherPerforinen
dc.subject.otherPore Forming Cytotoxic Proteinsen
dc.subject.otherReceptors, IgE.chemistry.immunologyen
dc.subject.otherRecombinant Fusion Proteinsen
dc.subject.otherT-Lymphocytes, Cytotoxic.immunologyen
dc.subject.otherTransfectionen
dc.titleThe use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of leukocyte biologyen
dc.identifier.affiliationAustin Research Institute, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages721-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8975874en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.